Zosano obtains lease financing for the purchase of capital equipment for the scale up and planned commercialization of M207 FREMONT, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company
FREMONT, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
FREMONT, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology
FREMONT, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
Completed enrollment for our M207-ADAM study with 344 subjects Presented additional analyses from the ZOTRIP pivotal study on pain relief and recurrence at the 2018 American Headache Society (AHS) meeting Published M207 nonclinical data in multiple leading scientific journals FREMONT, Calif. , Aug.
FREMONT, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’s intracutaneous zolmitriptan delivery FREMONT, Calif. , July 17, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated
Key findings on receptor and binding kinetics also to be presented in a poster and oral presentation FREMONT, Calif. , June 27, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid
Peer reviewed article evaluates effect of skin models on in vitro performance of ADAM FREMONT, Calif. , June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic
FREMONT, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied
